Gennex Lab.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE509C01026
NSEID:
BSEID: 531739

INR

12.50

-0.06 (-0.48%)

BSENSE

Dec 19

BSE+NSE Vol: 1.48 lacs

{
  "main_header": {
    "sid": 930938,
    "name": "Gennex Lab.",
    "stock_name": "Gennex Lab.",
    "full_name": "Gennex Laboratories Ltd",
    "name_url": "stocks-analysis/gennex-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "12.50",
    "chg": -0.06,
    "chgp": "-0.48%",
    "dir": -1,
    "prev_price": "12.56",
    "mcapval": "308.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531739,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE509C01026",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "1.48 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gennex-lab-930938-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gennex Laboratories Faces Revised Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-downgraded-to-sell-amid-weak-financials-and-technical-signals-3759685",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GennexLaborator_mojoScore_3759685.png",
        "date": "2025-12-16 08:41:22",
        "description": "Gennex Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has experienced a shift in market evaluation following a detailed reassessment of its financial performance, valuation, technical indicators, and overall quality metrics. This article explores the factors influencing the recent changes in the company’s market standing and what investors should consider in light of these developments."
      },
      {
        "title": "Gennex Lab. Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-lab-upgraded-from-sell-to-hold-by-marketsmojo-on-12-nov-2025-3741157",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GennexLab_mojoScore_3741157.png",
        "date": "2025-12-02 10:09:33",
        "description": "Gennex Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment follows a period marked by contrasting financial trends and valuation metrics, prompting a reassessment of the company’s standing within its sector and relative to market benchmarks."
      },
      {
        "title": "Why is Gennex Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gennex-lab-fallingrising-3722166",
        "imagepath": "",
        "date": "2025-11-22 01:12:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Gennex Laboratories has experienced a significant correction over the past week, with its stock price declining by 12.88%, in stark contrast to the Sensex’s modest gain of 0.79% during the same period. This divergence highlights the stock’s relative weakness amid a generally stable market environment. Over the last month, the stock has also lagged, posting a 3.58% loss while the Sensex advanced by 0.95%. Year-to-date figures further underline this underperformance, with Gennex down 15.97% compared to the Sensex’s 9.08% gain. The one-year performance gap is even more pronounced, with the stock falling 27.58% while the benchmark rose 10.47%.</p>\n<p>Despite these recent setbacks, it is important to note that Gennex Laboratories has del..."
      },
      {
        "title": "Gennex Laboratories Faces Financial Challenges Amid Mixed Market Performance Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-financial-trend-shifts-from-flat-to-negative-amid-declining-profit-metrics-3711944",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GennexLaborator_fintrenddot_3711944.png",
        "date": "2025-11-18 13:01:30",
        "description": "Gennex Laboratories has faced challenges in its financial performance for the quarter ending September 2025, with a decline in key metrics. Despite a record Profit After Tax, the company reported a drop in Profit Before Tax and a low Return on Capital Employed, alongside increased leverage and mixed market performance."
      },
      {
        "title": "Why is Gennex Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gennex-lab-fallingrising-3708854",
        "imagepath": "",
        "date": "2025-11-17 23:08:37",
        "description": "As of 17-Nov, Gennex Laboratories Ltd is experiencing a decline in its stock price, currently at 15.05, which represents a decrease of 0.71 or 4.51%. The stock has underperformed its sector today by 4.79%, and while it is trading higher than its 50-day, 100-day, and 200-day moving averages, it is lower than its 5-day and 20-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume on 14 November falling by 61.21% compared to the 5-day average. Over the past year, the stock has seen a substantial decline of 21.12%, contrasting with a positive return of 9.50% from the benchmark index, Sensex.\n\nBroader Market Context: In the short term, Gennex Laboratories Ltd has underperformed the Sensex, which has gained 1.69% over the past week while Gennex has only decreased by 0.40%. Year-to-date, the stock has declined by 7.89%, significantly lagging behind the ..."
      },
      {
        "title": "How has been the historical performance of Gennex Lab.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-gennex-lab-3703652",
        "imagepath": "",
        "date": "2025-11-15 00:08:27",
        "description": "Answer:\nThe historical performance of Gennex Lab shows significant growth in net sales and profitability over the years.\n\nBreakdown:\nGennex Lab's net sales have increased from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, demonstrating a consistent upward trend. Total operating income has mirrored this growth, rising from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25. However, the raw material costs have also escalated, reaching 100.59 Cr in Mar'25 from 34.19 Cr in Mar'21. Despite rising costs, the operating profit (PBDIT) has shown improvement, climbing to 27.14 Cr in Mar'25 from 4.20 Cr in Mar'20. Profit before tax has also increased significantly, reaching 21.40 Cr in Mar'25 compared to 2.55 Cr in Mar'20. The profit after tax has followed suit, growing from 1.86 Cr in Mar'20 to 18.12 Cr in Mar'25. The company's total assets have expanded from 56.94 Cr in Mar'20 to 255.86 Cr in Mar'25, while total liabilities ha..."
      },
      {
        "title": "How has been the historical performance of Gennex Lab.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-gennex-lab-3695482",
        "imagepath": "",
        "date": "2025-11-13 00:26:52",
        "description": "Answer:\nThe historical performance of Gennex Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.\n\nBreakdown:\nGennex Lab's net sales have increased from 69.55 Cr in March 2023 to 137.90 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 69.55 Cr in March 2023 to 137.90 Cr in March 2025. However, the raw material costs also surged, from 46.91 Cr in March 2023 to 100.59 Cr in March 2025, indicating increased operational expenses. Despite this, the operating profit (PBDIT) rose significantly from 8.64 Cr in March 2023 to 27.14 Cr in March 2025, although the operating profit margin decreased from 13.17% to 12.12%. Profit before tax also saw a notable increase from 6.37 Cr in March 2023 to 21.40 Cr in March 2025, leading to a profit after tax of 18.12 Cr in March 2025, up from..."
      },
      {
        "title": "Why is Gennex Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-gennex-lab-fallingrising-3693607",
        "imagepath": "",
        "date": "2025-11-12 23:00:03",
        "description": "As of 12-Nov, Gennex Laboratories Ltd is experiencing a price increase, currently at 15.96, with a change of 0.26, representing a rise of 1.66%. The stock has shown strong performance recently, gaining 11.92% over the last three days and outperforming its sector by 0.68% today. Additionally, Gennex Laboratories has delivered a remarkable 30.93% return over the past month, significantly outpacing the Sensex's 2.38% increase. However, it is important to note that the stock has seen a decline of 2.33% year-to-date and 20.75% over the past year. The stock is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Gennex Laboratories' short-term return of 5.63% over the past wee..."
      },
      {
        "title": "Gennex Laboratories Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-forms-golden-cross-signaling-potential-bullish-breakout-3693091",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GennexLaborator_goldencross_3693091.png",
        "date": "2025-11-12 18:00:57",
        "description": "Gennex Laboratories has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock has shown strong short-term performance, with notable gains over the past week and month. Despite a challenging one-year performance, technical indicators suggest a bullish sentiment, attracting investor interest amid its recovery phase."
      }
    ],
    "total": 132,
    "sid": "930938",
    "stock_news_url": "https://www.marketsmojo.com/news/gennex-laboratories-930938"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "16-Dec-2025",
      "details": "Notice is hereby given that in pursuance of SEBI (PIT) Regulations 2015 and Companys code of conduct for Regulating Monitoring and Reporting of Trading by Insiders the Trading Window for dealing in the securities of the Company shall remain closed from January 01 2026 till 48 hours after the public announcement through Board of Directors in their meeting held for announcing the Un-audited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended December 31 2025 along with other matters for which Trading Window is required to be closed. The Board Meeting Date to approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Third Quarter and Nine months ended December 31 2025 will be informed in due course. All Promoters/Designated/Connected persons are advised not to trade in the securities of the Company directly or indirectly during the aforesaid period of Closure of Trading Window.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "17-Nov-2025",
      "details": "Pursuant to Regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2025 announced by the Board of Directors in its meeting held on Friday November 14 2025. Financial Results had been published in both Business Standard (English) and Saksham (Telugu - Local) on November 16/17 2025. We request you to take the above information on record and acknowledge receipt of the same.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "In just concluded meeting of Board of Directors the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the quarter and half year ended September 30 2025; 2. Limited Review Reports from the Statutory Auditors on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30 2025; 3. Other Business We hereby submit that the Board Meeting had commenced at 4.00 PM and concluded at 5.00 PM. This information is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:10</strong> stock split, ex-date: 14 Dec 09",
          "dt": "2009-12-14",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:2</strong> rights issue, ex-date: 21 Jul 22",
          "dt": "2022-07-21",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Gennex Laboratories Faces Revised Market Assessment Amid Mixed Financial and Technical Signals

2025-12-16 08:41:22

Gennex Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has experienced a shift in market evaluation following a detailed reassessment of its financial performance, valuation, technical indicators, and overall quality metrics. This article explores the factors influencing the recent changes in the company’s market standing and what investors should consider in light of these developments.

Gennex Lab. Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-02 10:09:33

Gennex Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment follows a period marked by contrasting financial trends and valuation metrics, prompting a reassessment of the company’s standing within its sector and relative to market benchmarks.

Why is Gennex Lab. falling/rising?

2025-11-22 01:12:08

Recent Price Movement and Market Comparison

Gennex Laboratories has experienced a significant correction over the past week, with its stock price declining by 12.88%, in stark contrast to the Sensex’s modest gain of 0.79% during the same period. This divergence highlights the stock’s relative weakness amid a generally stable market environment. Over the last month, the stock has also lagged, posting a 3.58% loss while the Sensex advanced by 0.95%. Year-to-date figures further underline this underperformance, with Gennex down 15.97% compared to the Sensex’s 9.08% gain. The one-year performance gap is even more pronounced, with the stock falling 27.58% while the benchmark rose 10.47%.

Despite these recent setbacks, it is important to note that Gennex Laboratories has del...

Gennex Laboratories Faces Financial Challenges Amid Mixed Market Performance Trends

2025-11-18 13:01:30

Gennex Laboratories has faced challenges in its financial performance for the quarter ending September 2025, with a decline in key metrics. Despite a record Profit After Tax, the company reported a drop in Profit Before Tax and a low Return on Capital Employed, alongside increased leverage and mixed market performance.

Why is Gennex Lab. falling/rising?

2025-11-17 23:08:37

As of 17-Nov, Gennex Laboratories Ltd is experiencing a decline in its stock price, currently at 15.05, which represents a decrease of 0.71 or 4.51%. The stock has underperformed its sector today by 4.79%, and while it is trading higher than its 50-day, 100-day, and 200-day moving averages, it is lower than its 5-day and 20-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume on 14 November falling by 61.21% compared to the 5-day average. Over the past year, the stock has seen a substantial decline of 21.12%, contrasting with a positive return of 9.50% from the benchmark index, Sensex. Broader Market Context: In the short term, Gennex Laboratories Ltd has underperformed the Sensex, which has gained 1.69% over the past week while Gennex has only decreased by 0.40%. Year-to-date, the stock has declined by 7.89%, significantly lagging behind the ...

How has been the historical performance of Gennex Lab.?

2025-11-15 00:08:27

Answer: The historical performance of Gennex Lab shows significant growth in net sales and profitability over the years. Breakdown: Gennex Lab's net sales have increased from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, demonstrating a consistent upward trend. Total operating income has mirrored this growth, rising from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25. However, the raw material costs have also escalated, reaching 100.59 Cr in Mar'25 from 34.19 Cr in Mar'21. Despite rising costs, the operating profit (PBDIT) has shown improvement, climbing to 27.14 Cr in Mar'25 from 4.20 Cr in Mar'20. Profit before tax has also increased significantly, reaching 21.40 Cr in Mar'25 compared to 2.55 Cr in Mar'20. The profit after tax has followed suit, growing from 1.86 Cr in Mar'20 to 18.12 Cr in Mar'25. The company's total assets have expanded from 56.94 Cr in Mar'20 to 255.86 Cr in Mar'25, while total liabilities ha...

How has been the historical performance of Gennex Lab.?

2025-11-13 00:26:52

Answer: The historical performance of Gennex Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025. Breakdown: Gennex Lab's net sales have increased from 69.55 Cr in March 2023 to 137.90 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 69.55 Cr in March 2023 to 137.90 Cr in March 2025. However, the raw material costs also surged, from 46.91 Cr in March 2023 to 100.59 Cr in March 2025, indicating increased operational expenses. Despite this, the operating profit (PBDIT) rose significantly from 8.64 Cr in March 2023 to 27.14 Cr in March 2025, although the operating profit margin decreased from 13.17% to 12.12%. Profit before tax also saw a notable increase from 6.37 Cr in March 2023 to 21.40 Cr in March 2025, leading to a profit after tax of 18.12 Cr in March 2025, up from...

Why is Gennex Lab. falling/rising?

2025-11-12 23:00:03

As of 12-Nov, Gennex Laboratories Ltd is experiencing a price increase, currently at 15.96, with a change of 0.26, representing a rise of 1.66%. The stock has shown strong performance recently, gaining 11.92% over the last three days and outperforming its sector by 0.68% today. Additionally, Gennex Laboratories has delivered a remarkable 30.93% return over the past month, significantly outpacing the Sensex's 2.38% increase. However, it is important to note that the stock has seen a decline of 2.33% year-to-date and 20.75% over the past year. The stock is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Gennex Laboratories' short-term return of 5.63% over the past wee...

Gennex Laboratories Forms Golden Cross, Signaling Potential Bullish Breakout

2025-11-12 18:00:57

Gennex Laboratories has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock has shown strong short-term performance, with notable gains over the past week and month. Despite a challenging one-year performance, technical indicators suggest a bullish sentiment, attracting investor interest amid its recovery phase.

View All News

Announcement

Closure of Trading Window

16-Dec-2025 | Source : BSE

Notice is hereby given that in pursuance of SEBI (PIT) Regulations 2015 and Companys code of conduct for Regulating Monitoring and Reporting of Trading by Insiders the Trading Window for dealing in the securities of the Company shall remain closed from January 01 2026 till 48 hours after the public announcement through Board of Directors in their meeting held for announcing the Un-audited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended December 31 2025 along with other matters for which Trading Window is required to be closed. The Board Meeting Date to approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Third Quarter and Nine months ended December 31 2025 will be informed in due course. All Promoters/Designated/Connected persons are advised not to trade in the securities of the Company directly or indirectly during the aforesaid period of Closure of Trading Window.

Announcement under Regulation 30 (LODR)-Newspaper Publication

17-Nov-2025 | Source : BSE

Pursuant to Regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2025 announced by the Board of Directors in its meeting held on Friday November 14 2025. Financial Results had been published in both Business Standard (English) and Saksham (Telugu - Local) on November 16/17 2025. We request you to take the above information on record and acknowledge receipt of the same.

Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025

14-Nov-2025 | Source : BSE

In just concluded meeting of Board of Directors the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the quarter and half year ended September 30 2025; 2. Limited Review Reports from the Statutory Auditors on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30 2025; 3. Other Business We hereby submit that the Board Meeting had commenced at 4.00 PM and concluded at 5.00 PM. This information is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same.